Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoadjuvant Operable Breast Cancer × palbociclib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 149 Neoplasm Metastasis 17 Ovarian Neoplasms 6 Neoplasms 6 Breast Diseases 5 Triple Negative Breast Neoplasms 3 Prostatic Neoplasms 3 Pancreatic Neoplasms 3 Head and Neck Neoplasms 3 Endometrial Neoplasms 3 Advanced Breast Cancer 3 Squamous Cell Carcinoma of Head and Neck 2 Sarcoma 2 Recurrence 2 Neoplasms by Site 2 Lung Neoplasms 2 Inflammation 2 Hereditary Sensory and Autonomic Neuropathies 2 Fallopian Tube Neoplasms 2 Estrogen Receptor-positive Breast Cancer 2 Colorectal Neoplasms 2 Cardiovascular Diseases 2 Carcinoma, Ovarian Epithelial 2 Carcinoma, Non-Small-Cell Lung 2 Brain Neoplasms 2 Venous Thromboembolism 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Untreated Operable Early Breast Cancer 1 Unilateral Breast Neoplasms 1

Interventions

palbociclib 1 Letrozole 1 Fluorouracil 1 Epirubicin 1 Cyclophosphamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02400567 2022-03-15

NeoPAL

UNICANCER

Phase 2 Completed

Neoadjuvant Operable Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡